PKCε-CREB-Nrf2 signalling induces HO-1 in the vascular endothelium and enhances resistance to inflammation and apoptosis by Mylroie, H. et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PKC1-CREB-Nrf2 signalling induces HO-1 in the
vascular endothelium and enhances resistance to
inflammation and apoptosis
Hayley Mylroie1, Odile Dumont1†, Andrea Bauer1†, Clare C. Thornton1†, John Mackey1†,
Damien Calay1†, Shahir S. Hamdulay1, Joan R. Choo1, Joseph J. Boyle1, Allen M. Samarel2,
Anna M. Randi1, Paul C. Evans3, and Justin C. Mason1*
1Vascular Sciences, Imperial Centre for Translational and Experimental Medicine, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, Du Cane Road, London
W12 0NN, UK; 2The Cardiovascular Institute, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; and 3Department of Cardiovascular Sciences, University of Sheffield,
Sheffield, UK
Received 6 November 2014; revised 30 March 2015; accepted 3 April 2015; online publish-ahead-of-print 16 April 2015
Time for primary review: 34 days
Aims Vascular injury leading to endothelial dysfunction is a characteristic featureof chronic renal disease, diabetesmellitus, and
systemic inflammatory conditions, and predisposes to apoptosis and atherogenesis. Thus, endothelial dysfunction repre-
sents apotential therapeutic target foratherosclerosis prevention.Theobservation that activityof eitherproteinkinaseC
epsilon (PKC1) or haem oxygenase-1 (HO-1) enhances endothelial cell (EC) resistance to inflammation and apoptosis
led us to test the hypothesis that HO-1 is a downstream target of PKC1.
Methods
and results
Expression of constitutively active PKC1 in human EC significantly increased HO-1 mRNA and protein, whereas con-
versely aortas or cardiac EC from PKC1-deficient mice exhibited reduced HO-1 when compared with wild-type litter-
mates. Angiotensin II activated PKC1 and induced HO-1 via a PKC1-dependent pathway. PKC1 activation significantly
attenuated TNFa-induced intercellular adhesion molecule-1, and increased resistance to serum starvation-induced
apoptosis. These responses were reversed by the HO antagonist zinc protoporphyrin IX. Phosphokinase antibody
array analysis identified CREB1(Ser133) phosphorylation as a PKC1 signalling intermediary, and cAMP response
element-binding protein 1 (CREB1) siRNA abrogated PKC1-induced HO-1 up-regulation. Likewise, nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) was identified as a PKC1 target using nuclear translocation and DNA-binding
assays, and Nrf2 siRNA prevented PKC1-mediated HO-1 induction. Moreover, depletion of CREB1 inhibited PKC1-
induced Nrf2 DNA binding, suggestive of transcriptional co-operation between CREB1 and Nrf2.
Conclusions PKC1 activity in the vascular endothelium regulates HO-1 via a pathway requiring CREB1 and Nrf2. Given the potent
protective actions of HO-1, we propose that this mechanism is an important contributor to the emerging role of
PKC1 in the maintenance of endothelial homeostasis and resistance to injury.
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1. Introduction
The vascular endothelium exhibits remarkable functional diversity and
plasticity, both constitutively and in response to soluble, cellular, and
physical factors. In addition to sustaining blood flow, the endothelium
controls vascular permeability and angiogenesis, and maintains an anti-
coagulant and anti-adhesive surface. Endothelial homeostasis is closely
linked to well-being and its prolonged disruption is associated with a
variety of diseases. Endothelial dysfunction, such as that seen in patients
with diabetes mellitus, renal impairment, and systemic inflammatory
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diseases, is a critical early step in atherogenesis. Dysfunction reflects
endothelial injury and indicates failure to perform homeostatic functions.
Pathogenesis is multifactorial and includes excessive generation of react-
ive oxygen species that interact with and consume nitric oxide (NO),
generating peroxynitrite and resulting in oxidationof tetrahydrobiopterin
and promotion of NO uncoupling. Additional injurious factors include
low-density lipoproteins modified by oxidation, pro-inflammatory cyto-
kines, and complement activation. A vicious cycle of inflammation and
further oxidative stress results in increased endothelial permeability to
lipoproteins and monocytes, and ultimately to atherosclerotic plaque
development.1 Although therapeutic reversal of endothelial dysfunction
is clinically very attractive, achieving this is challenging and options
remain limited.
Haem oxygenase-1 (HO-1) is the inducible form of haem oxyge-
nase, and the rate-limiting factor in the catabolism of haem into biliver-
din, releasing free iron and carbonmonoxide.2 Biliverdin is converted to
bilirubin by biliverdin reductase, while the increased intracellular iron
induces expression of heavy chain ferritin, an iron-binding protein,3
along with the opening of Fe2+ export channels.4 Through their anti-
inflammatory, anti-apoptotic, and anti-oxidant actions, the products of
HO-1 enzyme activity play a central role in endothelial cytoprotective
responses.5 This is well illustrated by the severe phenotype reported
in human HMOX1 deficiency, manifested by generalized inflammation,
leucocytosis, haemolytic anaemia, and tissue iron deposition. There
was evidence of severe endothelial injury and dysfunction, associated
with abnormalities of coagulation–fibrinolysis and accelerated athero-
sclerosis.6,7 Human and rodent experimental data also suggest that
HO-1 activity is anti-atherogenic. Thus, crossing Hmox12/2 mice with
atherosclerosis prone ApoE-/- animals resulted in more extensive and
complex plaques,8 while HO-1 induction impeded atherogenesis and
stabilized plaques.9
The diversity of its protective actions has led to considerable interest
in therapeuticmodulationofHO-1.However, optimalmeans for target-
ing HO-1 or delivering its products remain to be determined, and func-
tional data demonstrating efficacy inman are very limited.5 The lowbasal
activity of the enzyme, combined with its inducibility, offers a potential
therapeutic approach, and hence the upstream signalling pathways
and transcriptional regulation of HO-1 remain a subject of intense inter-
est.5,10 Phosphoinositide 3 kinase (PI3K) and mitogen-activated protein
kinase (MAPK) pathways have been implicated inHO-1 regulation.10–12
Extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and c-Jun
N-terminal kinase (JNK) MAPK may act as both positive and negative
regulators of HO-1 in a cell type and agonist-specific manner.10,13
Protein kinase C is a family of phospholipid-dependent serine/threo-
nine kinases, divided on the basis of structure and response to phospha-
tidylserine, calcium, and diacylglycerol, into classical (a, b, and g), novel
(d, 1, h, and u), and atypical (z, i, and g) isoforms. Unique cell-specific
functions of individual isoforms have been described, reflecting differ-
ences within isoform structure, subcellular compartmentalization, and
PKC–target protein interactions.14 We reported that activation of the
novel isoform PKC1 enhances the resistance of human endothelial cells
(ECs) to pro-apoptotic and pro-inflammatory stimuli.15,16 This led us to
investigate the hypothesis that HO-1 represents an important down-
stream effector mechanism for the cytoprotective actions of PKC1. The
current study reveals that specific targeting of PKC1 in the vascular endo-
thelium activates a novel cAMP response element-binding protein
(CREB)-nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-dependent
signalling pathway, which induces HO-1 to enhance protection against
inflammation and apoptosis.
2. Methods
2.1 Reagents
Anti-HO-1 (Cambridge Biosciences Ltd, Cambridge, UK), anti-phospho-
PKCd(Thr505), anti-CREB, anti-phospho-CREB(Ser133) (Cell Signaling, Danvers,
MA, USA), anti-phospho-PKC1(Ser729) (Upstate Ltd, Dundee, UK), anti-PKC1,
and anti-Nrf2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). TNF-a was
from R&D Systems (Abingdon, UK); angiotensin II (Ang II) and zinc protopor-
phyrin IX (ZnPPIX) from Sigma-Aldrich (Poole, UK).
2.2 Human and murine cell culture
The use of human EC conformed to the principles outlined in the Declar-
ation of Helsinki, and was approved by the Hammersmith Hospitals
Research Ethics Committee (ref no. 06/Q0406/21). Following informed
consent, human umbilical vein ECs (HUVECs) were isolated and cultured
as described.17 To generate matched wild-type (WT) and PKC12/2 EC
lines, PKC1-deficient mice18 (gift from Prof. P. Parker, Kings College
London) were backcrossed on to a C57BL/6 background, and then
crossed with H-2Kb-tsA58 transgenic mice and the offspring crossed to
generate H-2Kb-tsA58/PKC12/2mice. The H-2Kb-tsA58 transgenic mice
(Immortomouse) were bred in house. The inducible tsA58 TAg allows
murine cardiac ECs (MCECs) cells to be rapidly expanded under permissive
conditions (338C), before switching to 378C for experimentation.19,20 Mice
were housed under controlled climactic conditions in microisolator cages
with autoclaved bedding. Irradiated food and drinking water were freely
available. All animalswere studied according to the guidelines fromDirective
2010/63/EUof the European Parliament, with ethical approval from Imperial
College LondonunderUKHomeOffice Licence number PPL 70/6722. Prior
to study,micewere sacrificedbyCO2 inhalation followedbycervical disloca-
tion.MCECswereobtained fromsix femalePKC12/2miceand sixPKC1+/+
littermate controls, using enzymatic digestion of hearts and positive selec-
tion with anti-endoglin and anti-Ig coated microbeads.20 EC phenotype
was validated by flow cytometry, which demonstrated.95% positive stain-
ing with Griffonia Simplicifolia Lectin I (Vector Laboratories, Peterborough,
UK) and anti-endoglin mAb MJ7/18 (Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IA, USA).
2.3 Adenoviral infection
The constitutively active (CA)-PKC1, CA-PKCd, dominant-negative
(DN)-PKC1, WT-PKC1, and Ad0 control adenoviruses were amplified in
human embryonic kidney 293A cells, purified, and titrated as described.21,22
HUVECs were infected by incubation with adenovirus in serum-free M199
for 2 h at 378C. The medium was replaced with M199 containing 10% fetal
bovine serum (FBS) and 7.5 mg/mL of EC growth factor (Sigma). Optimal
multiplicity of infection (MOI) for theCA-PKC1 adenovirus, expressed as in-
fectious units (ifu) per cell, was previously determined by immunoblotting.15
2.4 siRNA transfection
GeneFECTOR (3 : 50; VennNova, Parkland, FL, USA) and siRNA (40 nM
final) were diluted separately in Opti-MEM I (Invitrogen, Paisley, UK).
Equal volumes of siRNA andGeneFECTOR solutions were mixed and incu-
batedat r/t for 5 min. Transfection solutionswere addedtoHUVECscultured
inOpti-MEM Imedium.After incubation for 4 h, culturemediumwas replaced
with EGM2medium (Lonza,Wokingham,UK) overnight and thenwithM199/
10% FBS. CREB1 target sequence 1: 5′-AACCAAGTTGTTGTTCAAGCT-3′
(Qiagen Ltd, Sussex, UK). siGENOME SMART pooled oligonucleotides and
the siGENOMEcontrolnon-targeting siRNA#1were fromThermoScientific
Fisher, Waltham, MA, USA.
CREB1 pooled sequences:
(i) 5′-GAGAGAGGTCCGTCTAATG-3′;
(ii) 5′-CGTACAAACATACCAGATT-3′;
(iii) 5′-GAGTGGAGATGCAGCTGTA-3′;
(iv) 5′-TGACTTATCTTCTGATGCA-3′;
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Nrf2 pooled sequences:
(i) 5′-TGACAGAAGTTGACAATTA-3′
(ii) 5′-TAAAGTGGCTGCTCAGAAT-3′
(iii) 5′-CCAAAGAGCAGTTCAATGA-3′
(iv) 5′-GAGAAAGAATTGCCTGTAA-3′
2.5 Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed using an iCycler
(BioRad, Hercules, CA, USA) and data calculated in relation to the b-actin
and glyceraldehyde-3-phosphate dehydrogenase housekeeping genes.
DNase-1-digested total RNA (1 mg) was reverse-transcribed using 1 mM
oligo-dT and Superscript reverse transcriptase (Invitrogen). cDNAwas amp-
lified in a 25 mL reaction containing 5 mL of cDNA template diluted 1 : 30,
12.5 mL of SYBR supermix (BioRad), 5 pmol of sense and antisense gene-
specific primers, and H2O to adjust the volume. The cycling parameters
were 3 min at 958C, 40 cycles at 958C for 10 s, and 568C for 45 s. Primer
sequences: HO-1: forward 5′-TTCTATCACCCTCTGCCT-3′, reverse
5′-CCTCTTCACCTTCCCCAACA-3′. Nrf2: forward 5′-TACTCCCAGGT
TGCCCACA-3′, reverse 5′-CATCTACAAACGGGAATGTCTGC-3′.
2.6 Immunoblotting
Aortas were snap frozen in liquid nitrogen, ground-up, and lysed in RIPA
buffer containing a protein inhibitor cocktail, prior to gel-electrophoresis
and transferred to a nitrocellulose membrane (Roche Diagnostics, UK).
Immunoblotting of aortic and EC lysates was performed as described previ-
ously.22 To control for sample loading, membranes were re-probed with an
a-tubulin Ab. Relative levels of protein expression were quantified using
Lab-Works gel-pro (Ultra-Violet Products, Upland, CA, USA).
2.7 Phosphokinase antibody array
HUVECs were transfected with CA-PKC1 or Ad0 adenoviruses and
lysed after 16 h. Protein concentration was determined using a BioRad
protein assay kit and 150 mg of protein lysate used for the human phospho-
kinase Ab array kit (R&D Systems), performed as per the manufacturer’s
instructions. Membranes were developed with horseradish peroxidase-
conjugated streptavidin and visualized with a chemiluminescence substrate
(GE-Healthcare Life Sciences, Little Chalfont, UK).
2.8 Flow cytometry
Flow cytometry was performed as previously described in detail.17 intercellu-
lar adhesion molecule-1 (ICAM-1) was detected with mAb 6.5B5 (generated
in house) and FITC-rabbit-anti-mouse (Dako, Stockport, UK). The results are
expressed as the relative fluorescent intensity, representingmean fluorescent
intensity (MFI) with testmAb divided by theMFI using the secondary antibody
alone.
2.9 Nrf2 activation assays
A TransAM Nrf2 ELISA kit (Active Motif, Carlsbad, CA, USA) was used to
determine the transcriptional activation of Nrf2 as per the manufacturer’s
instructions. Nuclear extracts (5 mg) were added to a 96-well plate
pre-coatedwith an anti-oxidant response element (ARE) consensus-binding
oligonucleotide (5′-GTCACAGTGACTCAGCAGAATCTG-3′) and incu-
bated for 1 h at r/t. AWToligonucleotide was used as a binding competitor.
Primary antibody (1 : 1000) was added for 1 h at r/t and specific binding was
estimated by spectrophotometry, after incubation with a horseradish
peroxidase-conjugated antibody.
Nrf2nuclear translocationassayswereperformedwithHUVECscultured
on gelatin-coated coverslips and fixed in methanol. ECs treated with 10%
normal goat serum at 48C overnight were treated with rabbit anti-Nrf2 or
an isotype-matched control Ab, followed by goat anti-rabbit AlexaFluor
488 (Invitrogen) for 1 h, washing and staining with Draq5, and mounting in
Vectashield (Vector). Nrf2 translocation was analysed by confocal micros-
copy, using images obtained at ×40 magnification from 10 fields of view
perexperiment, andquantified after correcting forautofluorescenceandde-
fining threshold intensity from background fluorescence, with results pre-
sented as MFI.
2.10 Cell survival assay
Analysis of EC survival was performed using the Promega (Southampton,
UK) CellTiter96 [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay according to the manufac-
turer’s instructions. The assay was quantified by recording absorbance at
490 nm. Percent cell death was calculated as follows: cell death ¼ 100 2
(OD test/OD control × 100), where control represents EC cultured in
M199/20% FBS alone for the duration of the experiment.
2.11 Statistical analysis
Datawere groupedaccording to treatment and analysedusing theGraphPad
Prism Software (San Diego, CA, USA). Numerical data are presented as the
mean of individual experiments+ standard error (SEM). As indicated in the
figure legends, differences between treatments were evaluated using either
an unpaired Student’s t-test or a one-sample t-test to compare two columns,
while to evaluate three or more samples the one-way analysis of variance
(ANOVA) was used. A Bonferroni correction was used to correct for
multiple comparisons. A value of P, 0.05 was considered significant.
3. Results
3.1 PKC1 regulates HO-1 expression in EC
PKC1 is constitutively expressed in vascular EC and enhances resistance
to injury.15,16 To explore underlying mechanisms, and specifically to
investigate the hypothesis that the enzymeHO-1 contributes to the vas-
culoprotective actions of PKC1, we initially adopted a gain-of-function
approach. Transfection of a well-characterized adenoviral vector
(CA-PKC1-Adv), in which amino acids 154–163 were deleted in the
inhibitory pseudosubstrate domain to render PKC1 CA,21 resulted in
a significant increase in HO-1 transcript levels when compared with
a control adenovirus, maximal 16 h post-transfection of CA-PKC1
(Figure 1A). This response corresponded to an increase of the activated
phosphorylated form of PKC1(Ser729) in HUVECs infected with the
CA-PKC1-Adv, maximal at an MOI of 50–100 ifu/cell (Figure 1B).
Although basal levels of HO-1 protein in untreated HUVECs were
typically low or undetectable, a significant induction was seen 24 h fol-
lowing expression of CA-PKC1 (Figure 1B and C). HO-1 up-regulation
was maximal (up to six-fold) at 24 h, sustained at 48 h, and not seen
in cells transfected with Ad0 (Figure 1D). In contrast to CA-PKC1,
adenoviral expression of WT-PKC1 led to a minimal increase in phos-
phorylated PKC1(Ser729) and HO-1 protein (Figure 1E). Thus, induction
of HO-1 is proportionate to the activation of PKC1 (Figure 1F and G).
The PKC1-mediated increase of HO-1 protein was completely attenu-
ated by pretreatment with actinomycin D (not shown) and cyclohexi-
mide (see Supplementary material online, Figure S1A), confirming
dependence upon gene transcription and de novo protein synthesis. To
investigate physiological activation of this pathway, HUVECs were
treatedwith Ang II, previously reported to activate PKC1.23 Ang II treat-
ment resulted in a marked increase in phosphorylated PKC1(Ser729),
maximal after 15 min. Likewise, significant induction of HO-1 was
seen after 16 h (Figure 2A–C). To determine the role of PKC1 in
HO-1 induction, ECs were infected with DN-PKC1-Adv or Ad0 prior
to exposure to Ang II. PKC1 inhibition reduced the low-level constitu-
tive expression of HO-1 and also significantly attenuated the induction
afforded by Ang II (Figure 2D and E).
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Ofnote, PKCd activity has alsobeen linked toHO-1 induction inEC.24
To investigate a potential role for PKCd, we first demonstrated that
expression of CA-PKC1 did not lead to phosphorylation of PKCd
(see Supplementary material online, Figure S1B). Although transfection
of CA-PKCd increased PKCd phosphorylation at Thr505, it failed to
induce HO-1 in HUVEC (see Supplementary material online, Figure
S1C and D).
Next, PKC1-deficient mice were used to examine the effect of PKC1
deletion onHO-1. Themicewere bred on to a C57Bl/6 background for
10 generations prior to crossing with the H-2Kb-tsA58 transgenic mice.
This approach allowed the isolation of matched conditionally immorta-
lized cardiac EC from H-2Kb-tsA58/PKC12/2 animals and WT litter-
mates.20 HO-1 protein was detectable in WT EC, and expression
was significantly reduced in cells derived from the PKC1-deficient
mice (Figure 2F and G). Likewise, immunoblotting analysis of aortae har-
vested fromC57Bl/6 PKC1+/2, PKC12/2, andWT littermates revealed
a significant reduction inHO-1 protein of up to 60% (Figure 2H). The de-
pletion of HO-1 was equivalent in PKC1+/2 and PKC12/2 mice,
Figure 1 PKC1 activation induces HO-1. HUVECs were left untreated (UT) or transfected with Ad0 or CA-PKC1-Adv for up to 24 h (MOI 0–100 ifu/
cell), prior to lysis and quantification of (A) HO-1 mRNA by qRT-PCR at 16 h, or (B) HO-1 protein and phosphorylated PKC1(Ser729) by immunoblotting
after 24 h,with (C) a histogramshowingpooledquantificationdata fromfiveHO-1 immunoblot experiments. (D)HUVECswere leftUTor transfectedwith
Ad0 or CA-PKC1 (MOI 100) for up to 48 h andHO-1 analysed by immunoblotting (n ¼ 3). (E, F, andG) HUVECswere left UT or transfectedwith Ad0 or
WT-PKC1-Adv for up to 24 h (MOI 25 ifu/cell), prior to lysis and quantification of PKC1, PKC1(Ser729), and HO-1 by immunoblotting (n ¼ 3). Data are
presented as mean+ SEM normalized to the UT control except in (C), where densitometry data are presented relative to the maximal expression
with CA-PKC1 (MOI 100), on account of minimal basal HO-1 protein expression (ANOVA, *P, 0.05, **P, 0.01, ***P, 0.001).
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demonstrating the importance of PKC1, since loss of a single allele was
significant.
3.2 PKC1-induced signalling pathways and
HO-1
ERK1/2 and PI-3K/Akt signalling pathways may be activated by PKC1
and have been implicated in HO-1 regulation.12,15,16 However, in
human EC, neither MEK-1 inhibitor UO126 nor PI-3K antagonist
LY290042 affected the induction of HO-1 mRNA (see Supplementary
material online, Figure S2A and B) or protein (not shown) by
CA-PKC1. This result led to experiments seeking alternative signalling
intermediates, making use of a phosphokinase antibody array.
HUVECs were transfected with CA-PKC1 or Ad0 adenoviruses for
16 h and initially analysed by immunoblotting to confirm activation
and phosphorylation of PKC1(Ser729). These lysates were then used
to probe the array. In addition to the expected increase in ERK1/2
phosphorylation in CA-PKC1-transfected cells, there was also marked
Figure2 Effect of PKC1 activationordepletiononHO-1. (A)HUVECswere treatedwith vehicle (UT)orangiotensin II (100 nM) (Ang II) for 16 hprior to
analysis of PKC1, PKC1(Ser729), andHO-1 by immunoblotting, and quantification by densitometry of: (B) PKC1 phosphorylation and (C) HO-1 (n ¼ 3). (D)
HUVECs were infected with Ad0 or Ad-DN-PKC1 (MOI 100) prior to treatment with vehicle (UT) or Ang II for 16 h and analysis of HO-1 induction by
immunoblotting and (E) quantification by densitometry (n ¼ 3). (F ) Cardiac ECs fromWT and PKC12/2 mice were lysed and immunoblotted for PKC1,
HO-1, and tubulin. (G) The histogram shows densitometric quantification of HO-1 (n ¼ 6). (H ) Aortas from adult PKC12/2, PKC1+/2 mice, and WT
littermate controls (n ¼ 3) were harvested, snap frozen, and subsequently lysed and immunoblotted for HO-1 and tubulin. Data are presented as
mean+ SEM, corrected for tubulin expression, and normalized to the untreated or Ad0 control (A–D) and to WT control (G and H ) [one-sample
t-test (B, C, G, and H ), t-test (E), *P, 0.05, ***P, 0.001].
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Figure 3 Role of CREB1 in PKC1-mediated HO-1 induction. (A) HUVECs were transfected with CA-PKC1 or Ad0 (MOI 100) for 16 h prior to gener-
ationof lysates toprobe aphosphokinaseAbarray.Results for thephosphorylationof ERK1/2 andCREB1are shownandare representativeof two separate
experiments. (B)HUVECswere transfectedwithCA-PKC1orAd0 (MOI100) for 16 h and immunoblotted for phospho-CREB(Ser133), CREB1, and tubulin,
with (C) a histogram showing pooled quantification data fromfive experiments. (D) HUVECswere left UT or transfectedwith a single CREB1 siRNAoligo
(CREB1), pooledCREB1 siRNAoligos (CREB2), or control (Ctrl) siRNA (40 nM) for 24 h prior to transfectionwith control Ad0 orCA-PKC1 adenovirus
(MOI 100) for 16 h. HUVECs were lysed and HO-1 mRNA levels analysed by qRT-PCR. (E) HUVECs were transfected as above with Ctrl, CREB1, or
pooled CREB1 siRNAs, prior to analysis of HO-1 by immunoblotting. The figure shows a representative blot. Pooled HO-1 quantification data from at
least four individual experiments were corrected for tubulin expression where appropriate. Data are presented normalized to control-transfected
cells (mean+ SEM). One-sample t-test (C), ANOVA (D and E), *P, 0.05, **P, 0.01, ***P, 0.001.
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phosphorylation of CREB1 at Ser133 (Figure 3A). Subsequent immuno-
blotting experiments confirmed and quantified this response, with an
increase of phospho-CREB1 in excess of five-fold in PKC1-transfected
cells when compared with the Ad0 control (Figure 3B and C ).
3.3 CREB1 acts downstream of PKC1
to regulate HO-1
Next, siRNA was used to interrogate the function of CREB1 in HO-1
induction downstream of PKC1. A single oligonucleotide and a pool of
four distinct sequences depleted CREB1. The induction of HO-1
mRNA following expression of CA-PKC1 was attenuated by CREB1
depletion, a response not seen in EC transfected with control siRNA
(Figure 3D). Similarly, the up-regulation of HO-1 protein following
activationof PKC1was inhibited by theCREB1pooledoligonucleotides,
with a less marked and more variable response seen with the single
oligonucleotide (Figure 3E). These data indicate that CREB1 is a key
component in PKC1-mediated HO-1 regulation.
3.4 PKC1, Nrf2, and the regulation of HO-1
The importance of the transcription factor Nrf2 in HO-1 regulation led
us to investigate its potential role as a PKC1 target in EC. Expression of
CA-PKC1 in HUVEC induced Nrf2 nuclear translocation, a response
thatwas not seenwith theAd0control (Figure 4A andB). ADNA-binding
ELISA further demonstrated Nrf2 activation. A significant increase in
Nrf2 DNA binding above that seen following transfection of the
Ad0 control virus was observed following expression of CA-PKC1
(Figure 4C). Moreover, this response was suppressed by inclusion of a
competitive oligonucleotide corresponding to the consensus sequence
for Nrf2 binding. Next, a pool of four distinct siRNA oligonucleotides
was used to deplete Nrf2 (see Supplementary material online, Figure
S2D), and this abrogated the PKC1-dependent increase in HO-1
mRNA (Figure 5A). Further investigation suggested that Nrf2 is a down-
stream target of activated PKC1. Nrf2 depletion failed to prevent PKC1
phosphorylation in CA-PKC1-transfected HUVEC, while it attenuated
the CA-PKC1-mediated increase in HO-1 protein (Figure 5B and C).
Additional Nrf2 DNA-binding experiments suggested that PKC1
activates Nrf2 via CREB1. Specifically, depletion of CREB1 with siRNA
prevented the PKC1-mediated increase in Nrf2 DNA binding, a re-
sponse reproduced as expected by Nrf2 siRNA (Figure 5D).
3.5 PKC1 exerts cytoprotective and
anti-inflammatory effects via induction
of HO-1
In an effort to determine the functional significance of PKC1-mediated
HO-1 induction, two separate models were used. In the first, serum
starvation of HUVEC for 24 h resulted in up to 50% EC death. Overex-
pressionofCA-PKC1 reduced this cell loss from50 to25%, and this pro-
tection was not seen in cells treated with the Ad0 control (Figure 6A).
The role of increased HO-1 activity in the protection afforded by
PKC1 was supported by its reversal in the presence of HO antagonist
ZnPPIX (Figure 6A).
HO-1 also exerts important anti-inflammatory actions in the vascular
endothelium.5,25 TNFa-mediated induction of ICAM-1 was used as a
model response to investigate the role of HO-1 in PKC1-mediated
anti-inflammatory effects. Adenoviral transfection of unstimulated EC
in the presence or absence of ZNPPIX led to a modest non-significant
effect on ICAM-1 surface expression. Treatment of EC with TNF-a
resulted in a marked increase in cell surface ICAM-1, a response that
was significantly attenuated by expression of CA-PKC1 and not by the
Ad0 control virus (Figure 6B). Moreover, although ZnPPIX had no
effect on the induction of ICAM-1 by TNF-a, it reversed the anti-
inflammatory action of PKC1, again demonstrating the importance of
HO-1 as a PKC1 target gene.
4. Discussion
PKC1 activation is emerging as an important contributor to the
maintenance of vascular EC homeostasis, through its ability to regulate
Figure 4 PKC1 activation results in Nrf2 nuclear translocation. (A)
HUVECs were transfected with CA-PKC1 or Ad0 (MOI 100) for
16 h prior to staining with an anti-Nrf2 antibody and DRAQ-5
nuclear stain. Representative images are shown, and in (B) a histogram
of pooled nuclear fluorescence data from five individual experiments,
expressed asMFI of Nrf2 (mean+ SEM). (C) HUVECswere left UTor
transfectedwith CA-PKC1 orAd0 (MOI 100) for 16 h.Nuclear lysates
were generated and Nrf2 activation assessed using a DNA-binding
ELISA in the presence and absence of a competitive WT oligonucleo-
tide (WT), corresponding to the consensus sequence forNrf2 binding.
Pooled data (mean+ SEM) from at least four independent experi-
ments are shown, corrected for tubulin expressionwhere appropriate,
and normalized to Ad0-transfected control cells (t-test, *P, 0.05).
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anti-apoptotic and anti-inflammatory genes.15,16 A role for PKC1 in
VEGF-induced activation of Akt, Bcl-2, and eNOS, and in the protection
of EC against serum starvation via modulation of eNOS activity, has also
been reported.16,26,27 Moreover, when exposed to chronic hypoxia
PKC1-deficient mice exhibit endothelial dysfunction, with reduced
eNOS induction in pulmonary EC and increased vascular tone. This
leads to pulmonary hypertension, which can be reversed by inhalation
of NO.28 However, the precise role of PKC1-regulated signalling in
endothelial homeostasis, and its potential as a therapeutic target
remains to be determined. In the current study, we have identified a
novel ECPKC1-CREB-Nrf2 signalling pathway that up-regulates expres-
sionof thevasculoprotectiveenzymeHO-1andconfers cytoprotection.
In light of the severe vascular endothelial injury and accelerated athero-
sclerosis reported inHMOX1 deficiency,6,7 we believe that this pathway
is worthy of further study as an important contributor to endothelial
homeostasis and resistance to endothelial injury.
A gain- and loss-of-function approach revealed a close relationship
between PKC1 activity and HO-1 expression. Selective activation of
PKC1 using an adenoviral vector increased HO-1, whereas HO-1
protein was depleted in EC and aortas from PKC1-deficient mice,
when compared with WT littermates. Physiological agonists of PKC1
have not been extensively studied in the vascular endothelium. We
chose to investigate Ang II, an important vascular mediator which acti-
vates PKC1 in cardiomyocytes23 and up-regulates HO-1 in EC.29,30 In
addition to its role as a vasoconstrictor, Ang II activates intracellular sig-
nalling pathways to modulate the release of growth factors and cyto-
kines, and to influence cell growth and proliferation.31 We propose
that HO-1 induction by Ang II is part of a homeostatic response to
minimize potentially deleterious cardiovascular effects of Ang II, with
PKC1 acting as an important intermediary. Treatment of EC with Ang
II resulted in PKC1 phosphorylation and HO-1 induction, a response
inhibited by DN-PKC1. In addition to regulating oxidative stress,
increasedHO-1 activity is anti-inflammatory, attenuating Ang II-induced
PGE2 and F2a synthesis.32 VEGF also activates PKC1 in HUVEC andwe
have reported that DN-PKC1 prevents VEGF-mediated up-regulation
of the anti-apoptotic protein A1.15 However, inhibition of PKC1 did
Figure 5 A PKC1-CREB-Nrf2 signalling pathway regulates HO-1 expression in EC. (A) HUVECs were left UT or transfected with pooled Nrf2 or Ctrl
siRNAoligonucleotides (40 nM) for 24 hprior to transfectionwithAd0orCA-PKC1 for 16 h.HO-1mRNA levelswere analysedby qRT-PCR. Pooled data
are shown from three individual experiments and normalized to expression in EC transfected with Ad0 alone. (B and C) HUVECs were transfected with
Nrf2 or control siRNA as above, prior to transfectionwith Ad0 orCA-PKC1 for 24 h. HO-1 and phospho-PKC1(Ser729) were analysed by immunoblotting.
A representative immunoblot is shown (B), and the histogram (C) shows data from four individual experiments, corrected for tubulin expression, and nor-
malized to control-transfected cells. (D)Nuclear lysateswere obtained fromHUVECs pretreatedwith control,Nrf2, orCREB siRNAoligonucleotides for
24 h prior to 16 h transfection with Ad0 or CA-PKC1. Nrf2 translocation was assessed using a DNA-binding ELISA. Pooled data from four independent
experiments are shown (mean+ SEM) and normalized relative to Ad0-transfected control cells (ANOVA, *P, 0.05, **P, 0.01, ***P, 0.001).
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not attenuate HO-1 induction by VEGF (not shown), suggesting that
additional PKC isoforms may be involved,22 or that PKC1 activity is
not predominant for HO-1 regulation by VEGF and acts as a parallel
pathway.
We have reported that inhibition of MEK-1, the upstream kinase of
ERK1/2, attenuates PKC1-mediated induction of A1, A20, and Bcl-2,15
whereas the PI-3K antagonist LY290042 prevents celecoxib induction
of HO-1.12 However, pharmacological antagonists of both pathways
failed to prevent HO-1 up-regulation following PKC1 activation. This
led us to use a phosphokinase Ab array to identify alternative PKC1
targets, and predominant among these was phosphorylation of
CREB1. Although JNK and p38 MAPK have been associated with
HO-1 regulation,10,13 no activation of p38 was seen in the antibody
array and we have reported in EC that PKC1 activity inhibits JNK phos-
phorylation.15
CREB1, which belongs to the CREB/ATF family of transcription
factors, is predominantly located in thenucleus bound toCREand is acti-
vatedbyphosphorylation atSer133 in thekinase-inducible domain.CREB
is universally expressedwith roles in cell metabolism, differentiation and
survival, and in cell-specific responses to extracellular stimuli.33 We
found CREB1 to be constitutively expressed in human EC, and its phos-
phorylation was increased up to six-fold following PKC1 activation.
Moreover, depletion of CREB1 attenuated PKC1-mediated induction
of HO-1. In human breast cancer cell lines, a link between PKC1 and
CREB1 was suggested by the observation that PKC1 siRNA reduces
constitutive CREB1(Ser133) phosphorylation and Bcl-2 expression.34
Although the role of CREB1 in the vasculature remains to be fully
understood, it appears to be protective, as arterial disease in rodent
models of atherosclerosis, hypertension, and insulin resistance is
closely associated with loss of aortic CREB1.35 Moreover, targeted
cardiac expression of DNCREB1 enhances oxidative stress, mitochon-
drial dysfunction, apoptosis, and mortality in a murine model.36 These
data suggest that CREB1 is important for the regulation of diverse
protective genes. Indeed, in the vascular endothelium, CREB1 plays a
central role in VEGF-driven angiogenesis, maintenance of endothelial
barrier function, and in prostacyclin-induced cytoprotection,37,38 with
both VEGF and prostacyclin able to induce HO-1.39,40
The HMOX1 promoter, which comprises .10 kb, has binding sites
for a variety of transcription factors that regulate basal and induced ex-
pression. In addition, the E1 and E2 upstream enhancer regions include
ARE.10Nrf2, amember of theCap’n’Collar family of basic leucine zipper
(bZip) transcription factors, binds to and drives ARE-mediated induc-
tion of HO-1 and other phase II anti-oxidant enzymes.41 Expression of
CA-PKC1 in human EC led to specific nuclear translocation of Nrf2,
and increased binding of Nrf2 in nuclear lysates to an oligo containing
an ARE consensus site. Furthermore, siRNA depletion of Nrf2 abro-
gated PKC1-induced HO-1 mRNA and protein up-regulation,
whereas knockdown of either CREB1 or Nrf2 was able to attenuate
Nrf2 binding to the ARE consensus oligonucleotide. Although this sug-
gests that PKC1-CREB1-Nrf2 acts in a linear pathwaywith transcription-
al co-operation between CREB1 and Nrf2, further studies are required
to understand the precise molecular relationship between CREB1
and Nrf2.
CREB andNrf2 are bothmembers of the bZip family inwhich hetero-
dimerization is common. Indeed, heterodimerization betweenNrf2 and
ATF4 is involved in the induction of HO-1 by cadmium chloride.42 Thus,
a direct physical interactionmayoccur betweenNrf2 andCREB1 result-
ing in co-operation at the HMOX1 promoter. This is of particular rele-
vance in light of the demonstration that CREB1 is directly involved in
HO-1 transcription induced by oxidized phospholipids, via signalling
pathways including PKC.43However, such interactionsmay be cell type-
specific with a complex network reported in dendritic cells in which ac-
tivity of HO-1 and Nrf2 inhibits CREB1/ATF1 activation.44 In addition,
phosphorylation of Nrf2 by PKC might be important. However, this
interaction remains to be fully understood and may be both isoform
and cell type-specific. Although PKC-mediated phosphorylation of
Nrf2 at Serine 40 has been linked to HO-1 induction in cancer cell
lines, PKCd seems to be the isoform involved.45 Moreover, at least in
hepatoblastoma cells, PKC1 may phosphorylate Keap1 (INrf2) and so
Figure 6 PKC1-induced HO-1 is cytoprotective and anti-
inflammatory. (A) HUVECs seeded onto 24-well plates were trans-
fected with CA-PKC1 or Ad0 (MOI 100) for 24 h prior to culture in
M199/10% FBS or in serum-depleted medium (M199/0.1% FBS), and
in the presence or absence of the competitive HO inhibitor ZnPPIX
(20 mM) for 24 h. ECs were incubated with MTS reagent in M199/5%
FBS for 3 h and samples analysed on a plate reader at 490 nm.
Pooled data from three independent experiments are shown.
Change in the cell number is expressed as a percentage of the Ad0
control cultured in M199/10% FBS. (B) HUVECs were transfected as
above prior to challenge with TNF-a 1 ng/mL for 6 h+ZnPPIX.
ICAM-1 expression was quantified by flow cytometry. Pooled data
from four individual experiments are shown; changes in ICAM-1 are
expressed as MFI (mean+ SEM) (ANOVA, *P, 0.05, **P, 0.01,
***P, 0.001).
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target Nrf2 for degradation. Depletion of PKC1 in these cells, or
decreased expression in human lung or liver tumours, was associated
with increased expression of Nrf2 cytoprotective genes and enhanced
cell survival.46 In contrast to these findings, other studies have reported
that increased PKC1 expression in breast and lung carcinomas corre-
lates positively with pro-survival genes and aggressivemetastatic behav-
iour.47,48This relationshipbetweenPKC1 activity andpro-survival genes
more closely mirrors that found in the endothelium.15,16,26
The induction of HO-1 led us to explore its contribution to the
protective actions of PKC1. Expression of CA-PKC1 in EC attenuated
both TNFa-mediated up-regulation of ICAM-1 and apoptosis induced
by serum starvation. ZnPPIX, a pharmacological antagonist of HO
activity, inhibited at least partially the cytoprotection afforded by
PKC1 activation. These data suggest that HO-1 is one of a number of
PKC1-inducible protective genes,withothers known to include the anti-
apoptotic genes A1 and Bcl-2, and the anti-inflammatory A20 and
eNOS.15,16,26 The regulation of A1, A20, and Bcl-2 by PKC1 utilizes a
distinct downstream ERK1/2-NF-kB-dependent pathway, while the
anti-inflammatory effect of PKC1 activity is additionally strengthened
by its inhibition of TNFa-induced JNK phosphorylation.15
Current evidencedemonstrates thatPKC1 is able toenhancevascular
endothelial resistance to injury, via distinct signalling pathways including
those regulated by ERK1/2, PI-3K, Akt, and NF-kB, and mediated by an
array of downstream target genes. To these we have added induction
of HO-1 via a CREB1 and Nrf2-dependent pathway. Given the potent
cytoprotective actionsofHO-1 and its products, this observation signifi-
cantly extends the importance of PKC1 activity in the maintenance of
endothelial homeostasis and resistance to injury. The findings raise the
possibility that once completely defined, PKC1 signalling pathways in
the vascular endothelium may represent a novel target through which
the vascular endothelium can be therapeutically conditioned.
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